Search the Newsreel

FBIO Looks 125.0% Overvalued on GF Value™ Ahead of Q2 Earnings

Fortress Biotech (NASDAQ: FBIO) is set to release its Q2 earnings report on August 12, 2026, with analysts forecasting an EPS of -$0.20 and revenue of $18.3 million. The stock is currently deemed 125.0% overvalued by GuruFocus' GF Value™ metric, trading at $2.61 against …

Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview

Fortress Biotech Inc (FBIO) is expected to report a loss of 20 cents per share in its upcoming earnings. This article is a preview of the company's financial performance.

The Technical Signals Behind (FBIOP) That Institutions Follow

This article analyzes the technical signals for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), indicating a strong near-term sentiment that could lead to a long-term positive bias. It highlights a significant risk-reward setup targeting a 12.4% gain with …

Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Fortress Biotech Inc (FBIO), highlighting its current earnings forecast score of 8.00 within the Pharmaceuticals industry. Analysts have set an average price target of $10.75 for FBIO, with a "Buy" trend based on two analyst ratings. The …

Law firm investigates Fortress Biotech for poss...

A law firm, Levi & Korsinsky, has initiated an investigation into Fortress Biotech, Inc. regarding potential breaches of fiduciary duties. This inquiry is focused on the company's financial management and accountability, and shareholders are encouraged to seek legal advice without cost. The investigation could …

Fortress Biotech (FBIO) to Release Earnings on Thursday

Fortress Biotech (FBIO) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 13th, with analysts expecting a loss of $0.20 per share on revenue of $18.30 million. The company's previous quarter significantly beat EPS estimates but slightly missed revenue …

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)

Levi & Korsinsky, LLP has launched an investigation into Fortress Biotech, Inc. (NASDAQ: FBIO) regarding potential breaches of fiduciary duties by its officers and directors. Current FBIO shareholders are encouraged to seek additional information or contact Joseph E. Levi, Esq. to learn more about …

Fortress Biotech Just Netted $159 Million - Its Preferred Shares Could Be The Real Winner

Precision Trading with Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Risk Zones

This article analyzes Fortress Biotech Inc.'s (FBIOP) Series A preferred stock, highlighting its neutral near and mid-term readings but a strong long-term positive bias. It identifies an exceptional 48.2:1 risk-reward setup targeting a 12.8% gain versus 0.3% risk. The analysis provides AI-generated trading strategies …

FBIO|Fortress Biotech Inc|Price:3.301|Chg%:-0.049

This article provides a comprehensive stock analysis of Fortress Biotech Inc (FBIO), highlighting its strong fundamentals, high growth potential, and "fairly valued" status within the Pharmaceuticals industry. It notes high institutional ownership and a "Buy" rating from multiple analysts with a target price of …

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financing

Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics, in which Urica holds an equity position, closed an oversubscribed $130 million Series B financing. This funding will support the late-stage global clinical development and commercialization of dotinurad, a next-generation URAT1 inhibitor for …

Fortress Biotech Inc (FBIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Fortress Biotech Inc (FBIO), listing major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings. The data indicates significant stakes held by …

Fortress Biotech, Inc. Revenue Breakdown – NASDAQ:FBIO

Fortress Biotech, Inc. (NASDAQ: FBIO) generated $63.26 million in revenue last year, with its Journey segment contributing the most at $61.86 million. The United States was the primary source of revenue, accounting for the entire $63.26 million. This shows a slight increase in overall …

Fortress Biotech Inc (FBIO) Income Statement

This article provides an income statement for Fortress Biotech Inc (FBIO), detailing its quarterly and annual financial performance. It includes metrics such as total revenue, cost of revenue, operating expenses, and net income, alongside year-over-year comparisons. The page also offers FAQs on how to …

Fortress Biotech Inc (FBIO) Financial Health: Profitability & Balance Sheet Analysis

Fortress Biotech Inc (FBIO) has a robust financial score of 8.91, ranking 26 out of 155 in the Pharmaceuticals industry, indicating strong financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 22.06% and a net profit increase of …

FBIO|Fortress Biotech Inc|Price:3.340|Chg%:-0.090

Fortress Biotech Inc (FBIO) is trading at $3.34, down 2.62%. The company's fundamentals are considered healthy with high growth potential, and its valuation is seen as fairly valued within the Pharmaceuticals industry. Analysts have rated it a "Buy" with a target price of $11.00, …

Technical Reactions to FBIOP Trends in Macro Strategies

This article analyzes Fortress Biotech Inc. (NASDAQ: FBIOP) using AI models to provide technical reactions and trading strategies. It highlights divergent sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup. Three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are presented, along with …

CNB0 Bond Coupon Profile — Rate & Payments

This article provides a brief overview of the CNB0 bond coupon profile, detailing its interest rate and payment structure. It highlights the importance of the coupon as the interest rate paid on a bond by Fortress Biotech, Inc. for its 9.375% Series A Cumulative …